Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer.

Tunn UW, Bargelloni U, Cosciani S, Fiaccavento G, Guazzieri S, Pagano F

Urologia internationalis1 Jan 1998Cited by 37 (Europe PMC)

PMID9563139DOI10.1159/000056540PepBankPUB-09563139

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study18

18 results from studies that gave the peptide. 18 results from people.

01HumanRandomized controlled trialPharmacokinetics
In advanced prostate cancer, median leuprorelin Cmax was 20.8 ng/ml with the 3-month depot versus 10.7 ng/ml with the 1-month depot.
In plain wordsIn advanced prostate cancer, peak leuprorelin levels were higher with the 3-month depot than the 1-month depot.
Peptide
Leuprolide
Outcome
IncreasePeak serum leuprorelin concentration
Study
n = 42
Comparator
1-month depot 3.75 mg
Outcome group
Pharmacokinetics · Cancer
Studied dose
11.25 mg every 3 months · subcutaneousAs given in this study (human).
Measurements
Median peak serum concentration (Cmax) of leuprorelin
20.8 ng/ml
3-month depot (11.25 mg)
Median peak serum concentration (Cmax) of leuprorelin
10.7 ng/ml
1-month depot (3.75 mg)
Source sentences
Summary
The 3-month depot showed a higher median peak serum concentration (Cmax) of leuprorelin at 20.8 ng/ml than the 1-month depot at 10.7 ng/ml but, conversely, this did not influence the rise in serum testosterone levels.
2 context sentences(design, population, supporting numbers)
Summary · context
In an open, randomized phase II pharmacokinetic study conducted in Germany and Italy, a total of 42 patients with advanced or metastatic prostate cancer (PCa) were treated for 9 months with the luteinizing hormone-releasing hormone analogue (LH-RH-a) leuprorelin acetate depot in two different formulations.
Summary · context
Fifteen patients received the 1-month depot and 27 patients received the newly developed 3-month depot, containing 3.75 mg and 11.25 mg, respectively.
Report a problemFND-0956313904
02HumanRandomized controlled trialEfficacy outcome
In advanced prostate cancer, higher leuprorelin Cmax with the 3-month depot did not influence the testosterone rise compared with the 1-month depot.
In plain wordsIn advanced prostate cancer, higher peak leuprorelin levels with the 3-month depot did not alter testosterone rises versus the 1-month depot.
Peptide
Leuprolide
Outcome
No significant changeTestosterone rise between formulations
Study
n = 42
Comparator
1-month depot
Outcome group
Sex hormones and fertility · Cancer
Studied dose
11.25 mg every 3 months · subcutaneousAs given in this study (human).
Source sentences
Summary
The 3-month depot showed a higher median peak serum concentration (Cmax) of leuprorelin at 20.8 ng/ml than the 1-month depot at 10.7 ng/ml but, conversely, this did not influence the rise in serum testosterone levels.
2 context sentences(design, population, supporting numbers)
Summary · context
In an open, randomized phase II pharmacokinetic study conducted in Germany and Italy, a total of 42 patients with advanced or metastatic prostate cancer (PCa) were treated for 9 months with the luteinizing hormone-releasing hormone analogue (LH-RH-a) leuprorelin acetate depot in two different formulations.
Summary · context
Fifteen patients received the 1-month depot and 27 patients received the newly developed 3-month depot, containing 3.75 mg and 11.25 mg, respectively.
Report a problemFND-0956313905
03HumanRandomized controlled trialEfficacy outcome
In advanced prostate cancer, remission or stabilization was comparable with monthly and three-monthly leuprorelin depots, at 86.7% and 85.2%, respectively.
In plain wordsIn advanced prostate cancer, remission or stable disease was comparable between monthly and three-monthly leuprorelin depots.
Peptide
Leuprolide
Outcome
Direction not reportedBest response between depot formulations
Study
n = 42
Comparator
1-month depot 3.75 mg
Outcome group
Tumor growth · Cancer
Studied dose
11.25 mg every 3 months · subcutaneousAs given in this study (human).
Measurements
Best response (complete/partial remission or stabilization, EORTC criteria)
86.7%
1-month depot
Best response (complete/partial remission or stabilization, EORTC criteria)
85.2%
3-month depot
Source sentences
Summary
Based on European Organization for Research and Treatment of Cancer criteria, the best response in terms of complete/partial remissions and stabilization was comparable in the two arms at 86.7% (1-month depot) and 85.2% (3-month depot).
2 context sentences(design, population, supporting numbers)
Summary · context
In an open, randomized phase II pharmacokinetic study conducted in Germany and Italy, a total of 42 patients with advanced or metastatic prostate cancer (PCa) were treated for 9 months with the luteinizing hormone-releasing hormone analogue (LH-RH-a) leuprorelin acetate depot in two different formulations.
Summary · context
Fifteen patients received the 1-month depot and 27 patients received the newly developed 3-month depot, containing 3.75 mg and 11.25 mg, respectively.
Report a problemFND-0956313918
04HumanNon-randomized trialEfficacy outcome
In advanced prostate cancer, both leuprorelin depot formulations produced complete pituitary down-regulation.
In plain wordsIn advanced prostate cancer, both leuprorelin depot formulations suppressed pituitary activity.
Peptide
Leuprolide
Outcome
DecreasePituitary down-regulation
Study
n = 42
Comparator
Baseline
Outcome group
Sex hormones and fertility · Cancer
Studied dose
3.75 mg monthly or 11.25 mg every 3 months · subcutaneousAs given in this study (human).
Source sentences
Summary
In both groups, subcutaneous injections of leuprorelin acetate injected monthly or at 3-month intervals produced a complete down-regulation of the pituitary
2 context sentences(design, population, supporting numbers)
Summary · context
In an open, randomized phase II pharmacokinetic study conducted in Germany and Italy, a total of 42 patients with advanced or metastatic prostate cancer (PCa) were treated for 9 months with the luteinizing hormone-releasing hormone analogue (LH-RH-a) leuprorelin acetate depot in two different formulations.
Summary · context
Fifteen patients received the 1-month depot and 27 patients received the newly developed 3-month depot, containing 3.75 mg and 11.25 mg, respectively.
Report a problemFND-0956313901
05HumanNon-randomized trialEfficacy outcome
In advanced prostate cancer, both leuprorelin depots suppressed testosterone to <=50 ng/dl within the first month and maintained suppression for 9 months.
In plain wordsIn advanced prostate cancer, both leuprorelin depots suppressed testosterone within the first month and maintained suppression for 9 months.
Peptide
Leuprolide
Outcome
DecreaseTestosterone suppression
Study
n = 42
Comparator
Baseline
Outcome group
Sex hormones and fertility · Cancer
Studied dose
3.75 mg monthly or 11.25 mg every 3 months · subcutaneous · 9 monthsAs given in this study (human).
Measurements
Serum testosterone castrate range
≤ 50 ng/dl
both leuprorelin depots, reached within first month and maintained over 9 months
Source sentences
Summary
and led to persistent suppression of testosterone and dihydrotestosterone to the castrate range (< or = 50 ng/dl for testosterone) within the first month of treatment, which thereafter could be maintained over the entire observation period of 9 months.
2 context sentences(design, population, supporting numbers)
Summary · context
In an open, randomized phase II pharmacokinetic study conducted in Germany and Italy, a total of 42 patients with advanced or metastatic prostate cancer (PCa) were treated for 9 months with the luteinizing hormone-releasing hormone analogue (LH-RH-a) leuprorelin acetate depot in two different formulations.
Summary · context
Fifteen patients received the 1-month depot and 27 patients received the newly developed 3-month depot, containing 3.75 mg and 11.25 mg, respectively.
Report a problemFND-0956313902
06HumanNon-randomized trialEfficacy outcome
In advanced prostate cancer, both leuprorelin depots suppressed dihydrotestosterone to the castrate range within the first month and maintained suppression for 9 months.
In plain wordsIn advanced prostate cancer, both leuprorelin depots suppressed dihydrotestosterone within the first month and maintained suppression for 9 months.
Peptide
Leuprolide
Outcome
DecreaseDihydrotestosterone suppression
Study
n = 42
Comparator
Baseline
Outcome group
Sex hormones and fertility · Cancer
Studied dose
3.75 mg monthly or 11.25 mg every 3 months · subcutaneous · 9 monthsAs given in this study (human).
Source sentences
Summary
and led to persistent suppression of testosterone and dihydrotestosterone to the castrate range (< or = 50 ng/dl for testosterone) within the first month of treatment, which thereafter could be maintained over the entire observation period of 9 months.
2 context sentences(design, population, supporting numbers)
Summary · context
In an open, randomized phase II pharmacokinetic study conducted in Germany and Italy, a total of 42 patients with advanced or metastatic prostate cancer (PCa) were treated for 9 months with the luteinizing hormone-releasing hormone analogue (LH-RH-a) leuprorelin acetate depot in two different formulations.
Summary · context
Fifteen patients received the 1-month depot and 27 patients received the newly developed 3-month depot, containing 3.75 mg and 11.25 mg, respectively.
Report a problemFND-0956313903
07HumanNon-randomized trialEfficacy outcome
In advanced prostate cancer, more than 80% of patients in both leuprorelin depot arms showed an objective clinical response.
In plain wordsIn advanced prostate cancer, more than 80% in both leuprorelin depot arms showed an objective clinical response.
Peptide
Leuprolide
Outcome
Not applicableObjective clinical response
Study
n = 42
Outcome group
Tumor growth · Cancer
Studied dose
3.75 mg monthly or 11.25 mg every 3 months · subcutaneousAs given in this study (human).
Measurements
Patients with objective clinical response
> 80%
all patients in both arms
Source sentences
Summary
A marked decrease in median prostate-specific antigen levels of 97.8% (1-month depot) and 96.6% (3-month depot) compared with baseline was observed, indicating an objective clinical response for more than 80% of all patients in both arms.
2 context sentences(design, population, supporting numbers)
Summary · context
In an open, randomized phase II pharmacokinetic study conducted in Germany and Italy, a total of 42 patients with advanced or metastatic prostate cancer (PCa) were treated for 9 months with the luteinizing hormone-releasing hormone analogue (LH-RH-a) leuprorelin acetate depot in two different formulations.
Summary · context
Fifteen patients received the 1-month depot and 27 patients received the newly developed 3-month depot, containing 3.75 mg and 11.25 mg, respectively.
Report a problemFND-0956313912
08HumanNon-randomized trialSafety outcome
In advanced prostate cancer, the most common side effects in both leuprorelin depot groups were related to hormone deprivation.
In plain wordsIn advanced prostate cancer, the most common side effects in both leuprorelin depot groups were related to hormone deprivation.
Peptide
Leuprolide
Outcome
Not applicableHormone-deprivation side effects
Study
n = 42
Outcome group
Adverse events · Cancer
Studied dose
3.75 mg monthly or 11.25 mg every 3 months · subcutaneousAs given in this study (human).
Source sentences
Summary
The most common side effects in both treatment groups were related to hormone deprivation.
2 context sentences(design, population, supporting numbers)
Summary · context
In an open, randomized phase II pharmacokinetic study conducted in Germany and Italy, a total of 42 patients with advanced or metastatic prostate cancer (PCa) were treated for 9 months with the luteinizing hormone-releasing hormone analogue (LH-RH-a) leuprorelin acetate depot in two different formulations.
Summary · context
Fifteen patients received the 1-month depot and 27 patients received the newly developed 3-month depot, containing 3.75 mg and 11.25 mg, respectively.
Report a problemFND-0956313917
09HumanNon-randomized trialPharmacokinetics
In advanced prostate cancer, leuprorelin Cmax occurred at 3 h with the 3-month depot.
In plain wordsIn advanced prostate cancer, leuprorelin peaked at 3 hours with the 3-month depot.
Peptide
Leuprolide
Outcome
Not applicableTime to peak concentration, 3-month depot
Study
n = 27
Outcome group
Pharmacokinetics · Cancer
Studied dose
11.25 mg every 3 months · subcutaneousAs given in this study (human).
Measurements
Time to Cmax of leuprorelin
3 h
3-month depot
Source sentences
Summary
Cmax occurred at 3 h for the 3-month and at 1 h for the 1-month depot formulation.
2 context sentences(design, population, supporting numbers)
Summary · context
In an open, randomized phase II pharmacokinetic study conducted in Germany and Italy, a total of 42 patients with advanced or metastatic prostate cancer (PCa) were treated for 9 months with the luteinizing hormone-releasing hormone analogue (LH-RH-a) leuprorelin acetate depot in two different formulations.
Summary · context
Fifteen patients received the 1-month depot and 27 patients received the newly developed 3-month depot, containing 3.75 mg and 11.25 mg, respectively.
Report a problemFND-0956313906
10HumanNon-randomized trialPharmacokinetics
In advanced prostate cancer, constant leuprorelin release began on day 7 with the 3-month depot.
In plain wordsIn advanced prostate cancer, constant leuprorelin release began on day 7 with the 3-month depot.
Peptide
Leuprolide
Outcome
Not applicableConstant release onset, 3-month depot
Study
n = 27
Outcome group
Pharmacokinetics · Cancer
Studied dose
11.25 mg every 3 months · subcutaneousAs given in this study (human).
Measurements
Day constant release started
7 day
3-month depot, steady state
Source sentences
Summary
During the steady state, constant release could be detected, starting on day 3 and day 7 for the 1-month and 3-month depot, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
In an open, randomized phase II pharmacokinetic study conducted in Germany and Italy, a total of 42 patients with advanced or metastatic prostate cancer (PCa) were treated for 9 months with the luteinizing hormone-releasing hormone analogue (LH-RH-a) leuprorelin acetate depot in two different formulations.
Summary · context
Fifteen patients received the 1-month depot and 27 patients received the newly developed 3-month depot, containing 3.75 mg and 11.25 mg, respectively.
Report a problemFND-0956313909
11HumanNon-randomized trialEfficacy outcome
In advanced prostate cancer, median PSA decreased 96.6% from baseline with the 3-month leuprorelin depot.
In plain wordsIn advanced prostate cancer, median PSA decreased 96.6% from baseline with the 3-month leuprorelin depot.
Peptide
Leuprolide
Outcome
DecreasePSA reduction, 3-month depot
Study
n = 27
Comparator
Baseline
Outcome group
Tumor growth · Cancer
Studied dose
11.25 mg every 3 months · subcutaneousAs given in this study (human).
Measurements
Median PSA decrease from baseline
96.6%
3-month depot
Source sentences
Summary
A marked decrease in median prostate-specific antigen levels of 97.8% (1-month depot) and 96.6% (3-month depot) compared with baseline was observed, indicating an objective clinical response for more than 80% of all patients in both arms.
2 context sentences(design, population, supporting numbers)
Summary · context
In an open, randomized phase II pharmacokinetic study conducted in Germany and Italy, a total of 42 patients with advanced or metastatic prostate cancer (PCa) were treated for 9 months with the luteinizing hormone-releasing hormone analogue (LH-RH-a) leuprorelin acetate depot in two different formulations.
Summary · context
Fifteen patients received the 1-month depot and 27 patients received the newly developed 3-month depot, containing 3.75 mg and 11.25 mg, respectively.
Report a problemFND-0956313911
12HumanNon-randomized trialEfficacy outcome
In advanced prostate cancer, complete or partial remission or stabilization occurred in 85.2% with the 3-month leuprorelin depot.
In plain wordsIn advanced prostate cancer, 85.2% had remission or stable disease with the 3-month leuprorelin depot.
Peptide
Leuprolide
Outcome
Not applicableBest response, 3-month depot
Study
n = 27
Outcome group
Tumor growth · Cancer
Studied dose
11.25 mg every 3 months · subcutaneousAs given in this study (human).
Measurements
Best response (complete/partial remission or stabilization, EORTC criteria)
85.2%
3-month depot
Source sentences
Summary
Based on European Organization for Research and Treatment of Cancer criteria, the best response in terms of complete/partial remissions and stabilization was comparable in the two arms at 86.7% (1-month depot) and 85.2% (3-month depot).
2 context sentences(design, population, supporting numbers)
Summary · context
In an open, randomized phase II pharmacokinetic study conducted in Germany and Italy, a total of 42 patients with advanced or metastatic prostate cancer (PCa) were treated for 9 months with the luteinizing hormone-releasing hormone analogue (LH-RH-a) leuprorelin acetate depot in two different formulations.
Summary · context
Fifteen patients received the 1-month depot and 27 patients received the newly developed 3-month depot, containing 3.75 mg and 11.25 mg, respectively.
Report a problemFND-0956313914
13HumanNon-randomized trialEfficacy outcome
In advanced prostate cancer, 3% showed disease progression with the 3-month leuprorelin depot.
In plain wordsIn advanced prostate cancer, 3% had disease progression with the 3-month leuprorelin depot.
Peptide
Leuprolide
Outcome
Not applicableDisease progression, 3-month depot
Study
n = 27
Outcome group
Tumor growth · Cancer
Studied dose
11.25 mg every 3 months · subcutaneousAs given in this study (human).
Measurements
Disease progression
3%
3-month depot group
Source sentences
Summary
6.7% in the 1-month group and 3% in the 3-month depot group showed progression of the disease.
2 context sentences(design, population, supporting numbers)
Summary · context
In an open, randomized phase II pharmacokinetic study conducted in Germany and Italy, a total of 42 patients with advanced or metastatic prostate cancer (PCa) were treated for 9 months with the luteinizing hormone-releasing hormone analogue (LH-RH-a) leuprorelin acetate depot in two different formulations.
Summary · context
Fifteen patients received the 1-month depot and 27 patients received the newly developed 3-month depot, containing 3.75 mg and 11.25 mg, respectively.
Report a problemFND-0956313916
14HumanNon-randomized trialPharmacokinetics
In advanced prostate cancer, leuprorelin Cmax occurred at 1 h with the 1-month depot.
In plain wordsIn advanced prostate cancer, leuprorelin peaked at 1 hour with the 1-month depot.
Peptide
Leuprolide
Outcome
Not applicableTime to peak concentration, 1-month depot
Study
n = 15
Outcome group
Pharmacokinetics · Cancer
Studied dose
3.75 mg monthly · subcutaneousAs given in this study (human).
Measurements
Time to Cmax of leuprorelin
1 h
1-month depot
Source sentences
Summary
Cmax occurred at 3 h for the 3-month and at 1 h for the 1-month depot formulation.
2 context sentences(design, population, supporting numbers)
Summary · context
In an open, randomized phase II pharmacokinetic study conducted in Germany and Italy, a total of 42 patients with advanced or metastatic prostate cancer (PCa) were treated for 9 months with the luteinizing hormone-releasing hormone analogue (LH-RH-a) leuprorelin acetate depot in two different formulations.
Summary · context
Fifteen patients received the 1-month depot and 27 patients received the newly developed 3-month depot, containing 3.75 mg and 11.25 mg, respectively.
Report a problemFND-0956313907
15HumanNon-randomized trialPharmacokinetics
In advanced prostate cancer, constant leuprorelin release began on day 3 with the 1-month depot.
In plain wordsIn advanced prostate cancer, constant leuprorelin release began on day 3 with the 1-month depot.
Peptide
Leuprolide
Outcome
Not applicableConstant release onset, 1-month depot
Study
n = 15
Outcome group
Pharmacokinetics · Cancer
Studied dose
3.75 mg monthly · subcutaneousAs given in this study (human).
Measurements
Day constant release started
3 day
1-month depot, steady state
Source sentences
Summary
During the steady state, constant release could be detected, starting on day 3 and day 7 for the 1-month and 3-month depot, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
In an open, randomized phase II pharmacokinetic study conducted in Germany and Italy, a total of 42 patients with advanced or metastatic prostate cancer (PCa) were treated for 9 months with the luteinizing hormone-releasing hormone analogue (LH-RH-a) leuprorelin acetate depot in two different formulations.
Summary · context
Fifteen patients received the 1-month depot and 27 patients received the newly developed 3-month depot, containing 3.75 mg and 11.25 mg, respectively.
Report a problemFND-0956313908
16HumanNon-randomized trialEfficacy outcome
In advanced prostate cancer, median PSA decreased 97.8% from baseline with the 1-month leuprorelin depot.
In plain wordsIn advanced prostate cancer, median PSA decreased 97.8% from baseline with the 1-month leuprorelin depot.
Peptide
Leuprolide
Outcome
DecreasePSA reduction, 1-month depot
Study
n = 15
Comparator
Baseline
Outcome group
Tumor growth · Cancer
Studied dose
3.75 mg monthly · subcutaneousAs given in this study (human).
Measurements
Median PSA decrease from baseline
97.8%
1-month depot
Source sentences
Summary
A marked decrease in median prostate-specific antigen levels of 97.8% (1-month depot) and 96.6% (3-month depot) compared with baseline was observed, indicating an objective clinical response for more than 80% of all patients in both arms.
2 context sentences(design, population, supporting numbers)
Summary · context
In an open, randomized phase II pharmacokinetic study conducted in Germany and Italy, a total of 42 patients with advanced or metastatic prostate cancer (PCa) were treated for 9 months with the luteinizing hormone-releasing hormone analogue (LH-RH-a) leuprorelin acetate depot in two different formulations.
Summary · context
Fifteen patients received the 1-month depot and 27 patients received the newly developed 3-month depot, containing 3.75 mg and 11.25 mg, respectively.
Report a problemFND-0956313910
17HumanNon-randomized trialEfficacy outcome
In advanced prostate cancer, complete or partial remission or stabilization occurred in 86.7% with the 1-month leuprorelin depot.
In plain wordsIn advanced prostate cancer, 86.7% had remission or stable disease with the 1-month leuprorelin depot.
Peptide
Leuprolide
Outcome
Not applicableBest response, 1-month depot
Study
n = 15
Outcome group
Tumor growth · Cancer
Studied dose
3.75 mg monthly · subcutaneousAs given in this study (human).
Measurements
Best response (complete/partial remission or stabilization, EORTC criteria)
86.7%
1-month depot
Source sentences
Summary
Based on European Organization for Research and Treatment of Cancer criteria, the best response in terms of complete/partial remissions and stabilization was comparable in the two arms at 86.7% (1-month depot) and 85.2% (3-month depot).
2 context sentences(design, population, supporting numbers)
Summary · context
In an open, randomized phase II pharmacokinetic study conducted in Germany and Italy, a total of 42 patients with advanced or metastatic prostate cancer (PCa) were treated for 9 months with the luteinizing hormone-releasing hormone analogue (LH-RH-a) leuprorelin acetate depot in two different formulations.
Summary · context
Fifteen patients received the 1-month depot and 27 patients received the newly developed 3-month depot, containing 3.75 mg and 11.25 mg, respectively.
Report a problemFND-0956313913
18HumanNon-randomized trialEfficacy outcome
In advanced prostate cancer, 6.7% showed disease progression with the 1-month leuprorelin depot.
In plain wordsIn advanced prostate cancer, 6.7% had disease progression with the 1-month leuprorelin depot.
Peptide
Leuprolide
Outcome
Not applicableDisease progression, 1-month depot
Study
n = 15
Outcome group
Tumor growth · Cancer
Studied dose
3.75 mg monthly · subcutaneousAs given in this study (human).
Measurements
Disease progression
6.7%
1-month depot group
Source sentences
Summary
6.7% in the 1-month group and 3% in the 3-month depot group showed progression of the disease.
2 context sentences(design, population, supporting numbers)
Summary · context
In an open, randomized phase II pharmacokinetic study conducted in Germany and Italy, a total of 42 patients with advanced or metastatic prostate cancer (PCa) were treated for 9 months with the luteinizing hormone-releasing hormone analogue (LH-RH-a) leuprorelin acetate depot in two different formulations.
Summary · context
Fifteen patients received the 1-month depot and 27 patients received the newly developed 3-month depot, containing 3.75 mg and 11.25 mg, respectively.
Report a problemFND-0956313915

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer.

Summary

Results from this study18

Version history

Subjects

Publication types

MeSH terms